Nivolumab Provides Durable Responses in Patients With Metastatic DNA Mismatch Repair–Deficient or MSI-High Colorectal Cancer.
Recently, pembrolizumab received FDA approval for use as a single agent in patients with solid tumors that exhibit the mismatch repair–deficient (MMR-D)/microsatellite instable (MSI-H) phenotype. It was the first regulatory approval based on a molecular feature independent of the tumor entity. The current study of nivolumab, another PD-1 antibody, in MSI-H colorectal cancer confirms the […]
